Full Press Release Details
June 25, 2026
nutraceuticals
press clippings
podcast
perriman
NCT
Ladder17 podcast: How eXoZymes is Scaling as a Public Company
EXOZ Positive Sentiment
Ladder17 podcast: How eXoZymes is Scaling as a Public Company
Key Takeaway: The Ladder17 podcast discusses how eXoZymes is scaling its operations as a public company. The episode highlights the company's innovative strategies and engagement within the nutraceuticals sector. Insights from the podcast suggest a positive outlook for eXoZymes' growth trajectory.
Price reaction · baseline $7.14 (2026-06-24 close) · hit pre-market · 3 other EXOZ headline(s) in the window, move may be shared
day 0 close · peak
+3.6%
Market Sentiment Analysis
POSITIVE FACTORS
- eXoZymes is successfully scaling as a public company.
- The podcast highlights innovative strategies for growth.
- Engagement with the nutraceuticals sector is promising.
Frequently Asked Questions
What is the focus of the Ladder17 podcast episode?
The episode focuses on how eXoZymes is scaling its operations as a public company.
What sector is eXoZymes engaged in?
eXoZymes is engaged in the nutraceuticals sector.
What strategies are discussed in the podcast?
The podcast highlights innovative strategies for eXoZymes' growth.